242 related articles for article (PubMed ID: 19636021)
1. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
Anguiano A; Tuchman SA; Acharya C; Salter K; Gasparetto C; Zhan F; Dhodapkar M; Nevins J; Barlogie B; Shaughnessy JD; Potti A
J Clin Oncol; 2009 Sep; 27(25):4197-203. PubMed ID: 19636021
[TBL] [Abstract][Full Text] [Related]
2. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
Zhan F; Barlogie B; Arzoumanian V; Huang Y; Williams DR; Hollmig K; Pineda-Roman M; Tricot G; van Rhee F; Zangari M; Dhodapkar M; Shaughnessy JD
Blood; 2007 Feb; 109(4):1692-700. PubMed ID: 17023574
[TBL] [Abstract][Full Text] [Related]
3. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS.
Giovanella L; Taborelli M; Ceriani L; Zucca E; Cavalli F; Delaloye AB
Nucl Med Commun; 2008 Jun; 29(6):535-41. PubMed ID: 18458600
[TBL] [Abstract][Full Text] [Related]
4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.
Acharya CR; Hsu DS; Anders CK; Anguiano A; Salter KH; Walters KS; Redman RC; Tuchman SA; Moylan CA; Mukherjee S; Barry WT; Dressman HK; Ginsburg GS; Marcom KP; Garman KS; Lyman GH; Nevins JR; Potti A
JAMA; 2008 Apr; 299(13):1574-87. PubMed ID: 18387932
[TBL] [Abstract][Full Text] [Related]
5. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.
Davies FE; Dring AM; Li C; Rawstron AC; Shammas MA; O'Connor SM; Fenton JA; Hideshima T; Chauhan D; Tai IT; Robinson E; Auclair D; Rees K; Gonzalez D; Ashcroft AJ; Dasgupta R; Mitsiades C; Mitsiades N; Chen LB; Wong WH; Munshi NC; Morgan GJ; Anderson KC
Blood; 2003 Dec; 102(13):4504-11. PubMed ID: 12947006
[TBL] [Abstract][Full Text] [Related]
6. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.
Zhan F; Hardin J; Kordsmeier B; Bumm K; Zheng M; Tian E; Sanderson R; Yang Y; Wilson C; Zangari M; Anaissie E; Morris C; Muwalla F; van Rhee F; Fassas A; Crowley J; Tricot G; Barlogie B; Shaughnessy J
Blood; 2002 Mar; 99(5):1745-57. PubMed ID: 11861292
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.
Meissner T; Seckinger A; Rème T; Hielscher T; Möhler T; Neben K; Goldschmidt H; Klein B; Hose D
Clin Cancer Res; 2011 Dec; 17(23):7240-7. PubMed ID: 21986844
[TBL] [Abstract][Full Text] [Related]
8. MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS).
Xiao R; Cerny J; Devitt K; Dresser K; Nath R; Ramanathan M; Rodig SJ; Chen BJ; Woda BA; Yu H
Am J Surg Pathol; 2014 Jun; 38(6):776-83. PubMed ID: 24705315
[TBL] [Abstract][Full Text] [Related]
9. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.
Kubiczkova L; Kryukov F; Slaby O; Dementyeva E; Jarkovsky J; Nekvindova J; Radova L; Greslikova H; Kuglik P; Vetesnikova E; Pour L; Adam Z; Sevcikova S; Hajek R
Haematologica; 2014 Mar; 99(3):511-8. PubMed ID: 24241494
[TBL] [Abstract][Full Text] [Related]
10. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.
Bild AH; Parker JS; Gustafson AM; Acharya CR; Hoadley KA; Anders C; Marcom PK; Carey LA; Potti A; Nevins JR; Perou CM
Breast Cancer Res; 2009; 11(4):R55. PubMed ID: 19638211
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival.
Chi J; Ballabio E; Chen XH; Kušec R; Taylor S; Hay D; Tramonti D; Saunders NJ; Littlewood T; Pezzella F; Boultwood J; Wainscoat JS; Hatton CS; Lawrie CH
Biol Direct; 2011 May; 6():23. PubMed ID: 21592325
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
13. Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma.
Lacy MQ; Donovan KA; Heimbach JK; Ahmann GJ; Lust JA
Blood; 1999 Jan; 93(1):300-5. PubMed ID: 9864174
[TBL] [Abstract][Full Text] [Related]
14. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
[TBL] [Abstract][Full Text] [Related]
15. Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma.
Dutoit JC; Vanderkerken MA; Verstraete KL
Eur J Radiol; 2013 Sep; 82(9):1444-52. PubMed ID: 23726124
[TBL] [Abstract][Full Text] [Related]
16. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome.
Avet-Loiseau H; Li JY; Morineau N; Facon T; Brigaudeau C; Harousseau JL; Grosbois B; Bataille R
Blood; 1999 Oct; 94(8):2583-9. PubMed ID: 10515861
[TBL] [Abstract][Full Text] [Related]
17. Improved risk stratification in myeloma using a microRNA-based classifier.
Wu P; Agnelli L; Walker BA; Todoerti K; Lionetti M; Johnson DC; Kaiser M; Mirabella F; Wardell C; Gregory WM; Davies FE; Brewer D; Neri A; Morgan GJ
Br J Haematol; 2013 Aug; 162(3):348-59. PubMed ID: 23718138
[TBL] [Abstract][Full Text] [Related]
18. Low-risk identification in multiple myeloma using a new 14-gene model.
Chen T; Berno T; Zangari M
Eur J Haematol; 2012 Jul; 89(1):28-36. PubMed ID: 22620863
[TBL] [Abstract][Full Text] [Related]
19. New insights in the clinical biology of multiple myeloma.
Bataille R
Semin Hematol; 1997 Jan; 34(1 Suppl 1):23-8. PubMed ID: 9122743
[TBL] [Abstract][Full Text] [Related]
20. Replication pattern in cancer: asynchronous replication in multiple myeloma and in monoclonal gammopathy.
Amiel A; Kirgner I; Gaber E; Manor Y; Fejgin M; Lishner M
Cancer Genet Cytogenet; 1999 Jan; 108(1):32-7. PubMed ID: 9973921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
